

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MARDUEL ALIX (Last) (First) (Middle) ONE EMBARACDERO CENTER, SUITE 4050 (Street) SAN FRANCISCO CA 94111 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/19/2004	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/19/2004		C		1,698,274	A	(1)	1,698,274	I	See Remark

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series C Preferred Stock	(2)	04/19/2004		C		1,698,274		(3)	(1)	Common	1,698,274	(2)	0	I	See Remarks

Explanation of Responses:

- Not applicable
- Each Share is convertible without consideration into one (1) share of Common Stock.
- Immediately

Remarks:

Alix Marduel, Director, is a managing director ("md") of Alta BioPharma Management II, LLC ("ABMII") (which is the general partner of Alta BioPharma Partners II, L.P. ("ABPII")) and a manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBII"). She disclaims beneficial ownership of all such shares held by all of the foregoing funds, except to the extent of her proportionate pecuniary interests therein. Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds, including ABPII and AEBII. AP II is no longer a 10% owner. The respective md and managers of ABPII and AEBII exercise sole voting and investment powers over the shares held by such funds. Upon the closing of the Issuer's initial public offering, ABPII beneficially owns 1,632,012 shares of Common Stock and AEBII beneficially owns 66,262 shares of Common Stock. Jean Deleage, Alix Marduel and Farah Champi (collectively known as the "principals") are managing directors of ABMII and managers of AEBII. As managing directors and managers, they may be deemed to share voting and investment powers over the shares held by the aforementioned funds. The principals disclaim beneficial ownership of the shares held by ABPII and AEBII except to the extent of their proportionate pecuniary interests therein.

/s/ Fred Kurland, CFO of
Corcept Therapeutics
Incorporated attorney-in-fact

04/21/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.